Look­ing for the next mR­NA break­through, Mod­er­na taps Ab­Cellera in mys­te­ri­ous an­ti­body dis­cov­ery deal

Mod­er­na’s suc­cess with its Covid-19 vac­cine has bust­ed the dam open on a range of po­ten­tial mR­NA ther­a­peu­tics — and now the biotech is push­ing to keep the cut­ting edge in-house. A new part­ner­ship with stand­out an­ti­body dis­cov­ery out­fit Ab­Cellera could help keep the ball in the com­pe­ti­tion’s court.

Mod­er­na will part­ner with an­ti­body play­er Ab­Cellera on up to six undis­closed tar­gets for a range of mR­NA-en­cod­ed drugs har­vest­ed from Ab­Cellera’s bustling dis­cov­ery plat­form, the com­pa­nies said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER